

The year in cardiology 2018: valvular heart disease

Wojciech Wojakowski^{1*} and Helmut Baumgartner²

¹Division of Cardiology and Structural Heart Diseases, Medical University of Silesia, Ziolowa 45, 40-635 Katowice, Poland; and ²Department of Cardiology III – Adult Congenital and Valvular Heart Disease, University Hospital Muenster, Albert Schweitzer Campus 1, Building A1, 48149 Muenster, Germany

Received 13 October 2018; revised 20 November 2018; editorial decision 14 December 2018; accepted 16 December 2018

Preamble

In 2018, the publications on valvular heart disease (VHD) addressed all topics—epidemiology, diagnosis, therapy, and predictors of outcome—but were dominated by studies focusing on transcatheter treatment. Regarding mitral regurgitation (MR) two pivotal studies investigating transcatheter edge-to-edge repair for secondary MR as well as early clinical experience with transcatheter mitral valve replacement (TMVR) were published. Regarding aortic stenosis (AS) there is a clear trend towards the expansion of indications for transcatheter aortic valve implantation (TAVI) to intermediate and low-risk groups, bicuspid aortic valve (BAV) and failed surgically implanted bioprostheses. Tricuspid valve (TV) disease is a growing clinical problem associated with high morbidity and mortality. Isolated TV surgery has a high risk and is currently performed in a minority of patients. Novel therapies using the edge-to-edge approach or annuloplasty are being investigated.

Aortic stenosis

Transcatheter aortic valve implantation is rapidly evolving, and implantation numbers are steeply increasing. In Germany where all procedures are mandatorily registered in a quality control programme, more than 15 000 TAVI procedures were performed in 2016. The number more than tripled since 2011, while isolated surgical aortic valve replacement (SAVR) remained relatively stable with approximately 10 000 per year being performed now much less frequently than TAVI (Figure 1). Complication rates and mortality decreased continuously with overall in-hospital mortality being in 2016 for the first time similar for TAVI (2.6%) and SAVR (2.9%) despite the different risk profile of both patient groups.¹ Expanding adoption of TAVI across the risk strata is widespread both in Europe and the USA. Based on SURTAVI, Sapien3 Intermediate Risk and PARTNER 2A the safety and efficacy was established for intermediate risk and following the NOTION study the concept showed promising results



for low-risk patients.² Importantly, surgical risk scales used for both approaches tend to overestimate mortality for TAVI patients in all the risk strata even taking into consideration that low-risk patients undergoing TAVI are younger than SAVR (Figure 2). The recent FDA-approved low-risk TAVR trial prospectively studied the outcomes of transfemoral TAVI in the low-risk group (STS-PROM $\leq 3\%$) and compared the results to historical controls from the Society of Thoracic Surgeons (STS) database. No mortality and strokes at 30 days, low risk of paravalvular regurgitation as well as permanent pacemaker implantation (PPI) rates similar to SAVR were reported, however, frailty was an exclusion criterium.³ A sub-analysis of the randomized controlled SURTAVI trial evaluating patients with STS-PROM $< 3\%$ suggested that TAVI may achieve superior early clinical outcomes compared with SAVR.⁴ These findings support the need for an adequately powered randomized trial to compare TAVI with SAVR in patients at low operative risk. Apparently, in such a population with assumingly longer life expectancy, there is a clear need for data on the long-term durability because no follow-up beyond 2 years has so far been published for this population. Ongoing trials such as PARTNER3, Evolut R Low Risk and NOTION 2 with follow-up of 5–10 years will provide more data with this regard. Currently available long-term durability data for transcatheter aortic valves although promising are unfortunately limited by the poor survival of the high-risk early populations. Eltchaninoff et al.⁵ reported an incidence of structural valve deterioration of 3.2% and bioprosthetic valve failure of 0.58% at 8 years using the new European consensus definition. Holy et al.⁶ estimated from their series that the rate of bioprosthetic valve failure at 8 years was 7.9% for the actuarial and 4.5% for the actual analysis. However, long-term durability will remain one of the key concerns until we have more solid data.

One of the other concerns beyond durability is the need for PPI which is in most reports higher with TAVI than with SAVR. A recent systematic review demonstrated the highly variable risk of PPI (2.3–36.1%) due to new onset conduction abnormalities after TAVI.⁷ The risk tended to be lower after balloon-expandable than self-expandable valves. Procedural factors, such as the depth of

The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.

* Corresponding author. Tel: +48604188669, Fax: +48322523930, Email: wwojakowski@sum.edu.pl

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.




implantation, predilatation, distribution of calcifications, and pre-existing conduction abnormalities were important risk factors for PPI. The possible long-term impact of even mild paravalvular leak (PVL) and the necessity of access to coronary arteries in patients with long life expectancy must also be considered.

Severe periprocedural complications of TAVI requiring emergent cardiac surgery (mainly annular rupture, ventricular perforation, and valve embolization) are rare but remain approximately 1%⁸ to 2%.⁹

Early mortality remains high in such cases. Nevertheless, given these life-threatening complications, the 30-day survival rate exceeding 50% underlines the importance of an experienced and well-attuned heart team providing immediate access to surgical bailout procedures. One-year mortality remains high (78%). These numbers may also indicate that on-site cardiac surgery alone is not sufficient and the setup for emergency conversion requires further improvement. Complication rates and early mortality decrease with increasing

A



B




Figure 3 The estimated number of transcatheter aortic valve implantation candidates in Europe under current indications (A) and projected numbers after accepting low-risk indication (B). Reprinted from Durko et al.¹¹

procedure volume. In an analysis of German national quality assurance data, in-hospital mortality varied highly (0–16.7%) and was on average markedly higher with $5.6 \pm 5.0\%$ in hospitals performing <50 transfemoral TAVIs annually compared with $2.4 \pm 1.0\%$ with rather consistent results (range 0.5–3.7%) in hospitals with ≥ 200 procedures per year.¹⁰ These studies support the recommendation of performing TAVI in heart valve centres with departments of cardiac surgery on-site and sufficiently high volumes.⁸

Impact on the healthcare resources utilization is an important issue given the epidemiology of AS and currently expanding indications for TAVI. The estimated number of TAVI candidates in Europe under current indications exceeds 114 000 per year and assuming low-risk indication is accepted this number may increase to 177 000¹¹ (Figure 3).

Aortic stenosis and coronary artery disease (CAD) have common risk factors, and clinically overt CAD is present in approximately half of the patients undergoing TAVI or SAVR. Coronary artery disease impacts the outcomes of TAVI, but data are still lacking for recommendations whether and when to perform percutaneous coronary intervention—before, during, or after TAVI.¹² The usefulness of invasive physiological assessment of CAD significance in severe AS is also unclear due to the hypertrophy, increased end-diastolic pressure and impaired function of the microvasculature. However, recent data suggest that both fractional flow reserve as well as an instantaneous valve-free ratio (iFR) have good correlation with ischaemic burden in SPECT and might be useful in clinical decision making about the revascularization strategy before aortic valve intervention.¹³ In most centres, the revascularization is limited to large proximal vessels, but the completeness of revascularization can have a prognostic impact, and use of the residual SYNTAX score could improve the risk stratification.^{12,14}

Transcatheter treatment of severe BAV stenosis is associated with procedural challenges related to large volume and asymmetrically distributed calcifications, large aortic annulus, the presence of calcified raphe, and coexisting aortopathy. Such anatomy increases the risk of non-uniform valve expansion, under-expansion, aortic root injury, and PVL. Despite that, given the high prevalence of BAV in the population TAVI procedures are increasingly done in this population. Data from the German TAVI registry including 1424 patients showed reassuring clinical outcomes with similar 30-day mortality as in TV. In patients with BAV, there was, however, a higher rate of PVL while pacemaker implantation was less frequent.¹⁵

Transcatheter valve-in-valve (ViV) implantation has become an accepted alternative to redo surgery in patients with surgical bioprosthetic valve failure and should be considered depending on surgical risk, valve type and size (IIa, level of evidence C recommendation).¹⁶ The STS/ACC registry provided reassuring data on the safety of ViV. Such patients should have a meticulous follow-up with echocardiography because the post-procedural gradients are higher than for native valve TAVI (16 mmHg vs. 9 mmHg; $P < 0.001$). The follow-up in this study was limited to 1 year.¹⁷ Coronary obstruction following ViV procedures occurred in 2.3% patients enrolled in the Valve-in-Valve International Data (VIVID) Registry and was more frequent in stented bioprostheses with externally mounted leaflets and stentless biological valves as well as in patients with a virtual transcatheter valve to coronary ostium distance measured by computed tomography below 4 mm.¹⁸ Delayed coronary obstruction is an infrequent

(0.22%) complication of TAVI (more often in ViV procedures and with self-expanding valves) but related to a high risk of death and myocardial infarction. ViV is challenging in small surgical prostheses because of a high post-procedural gradient, and new concepts, such as using the high-pressure inflation of non-compliant balloon and fracturing of the prosthetic valve ring are evaluated.¹⁹

The antithrombotic regimen after TAVI remains a matter of debate and results of randomized controlled trials are still awaited. In patients who required oral anticoagulation with vitamin K antagonists (VKA) for atrial fibrillation, an observational study reported significantly less major, and life-threatening bleeding complications on VKA therapy only compared with those with additional single (SAPT) or dual antiplatelet therapy (DAPT). This difference was not outweighed by a reduction of embolic events thus favouring VKA monotherapy.²⁰ In a propensity-matched analysis comparing SAPT and DAPT in 1210 patients, at 30 days, VARC mortality, major vascular complications, and major bleedings were significantly lower in the SAPT group without a difference in prosthetic heart valve dysfunction after TAVI with a balloon-expandable valve favouring aspirin monotherapy when no anticoagulation is indicated.²¹

Data from the FRANCE-TAVI registry, on the other hand, showed that VKA are related to less bioprosthetic valve dysfunction in short-term follow-up.²² More research is required to define the optimal antithrombotic treatment after TAVI.

There are currently no convincing data that all patients with severe AS who have normal left ventricular function and are asymptomatic by history and during exercise testing may benefit from early valve replacement and current guidelines, therefore, recommend watchful waiting for these patients unless they present with particular risk factors.¹⁶ Retrospective analyses reporting a benefit from early surgery were mainly driven by the fact that a considerable number of patients did not undergo surgery in the conservative group when developing indications for intervention, mainly symptoms. This suggests that the worse outcome in the conservative group was primarily due to non-adherence to the guidelines. A retrospective cohort study including 300 patients with asymptomatic severe AS appears to support this assumption.²³ Nonadherent patients had significantly higher mortality and rate of hospital admission for heart failure (HF), while they underwent less frequently SAVR during follow-up. A recent analysis of the Heart Valve Clinic International Database reported that in asymptomatic patients with severe AS left ventricular (LV) ejection fraction (LVEF) <60% and peak aortic jet velocity >5 m/s were associated with increased all-cause and cardiovascular mortality suggesting that this population may benefit from early valve replacement,²⁴ but more data will be required for solid recommendations.

Recent guidelines modified the indications for surgery in asymptomatic severe AS.¹⁶ A new recommendation was added that SAVR should be considered when surgical risk is low, and patients present with severe pulmonary hypertension. The negative impact of pulmonary hypertension on long-term outcome was reported once more in a study including more than 1000 patients with severe AS supporting the guidelines.²⁵

Current guidelines do also no longer include the recommendation that surgery may be considered in asymptomatic patients with an increase in mean gradient >20 mmHg on exercise.¹⁶ This was based on pathophysiologic concerns and new studies questioning this recommendation. Goublaire et al.²⁶ did not find a difference in event-free

survival between asymptomatic patients (no symptoms on exercise testing) with or without stress-induced mean gradient increase >20 mmHg.

Untreated severe AS causes on the long-term progressive damage to other heart structures. Genereux *et al.* accordingly classified five stages of disease: no extravalvular cardiac damage (Stage 0), left ventricular damage (Stage 1), left atrial or mitral valve damage (Stage 2), pulmonary vasculature or TV damage (Stage 3), and right ventricular damage (Stage 4). One-year mortality increased continuously from 4.4% (Stage 0) to 24.5% (Stage 4). The extent of cardiac damage was independently associated with increased mortality after aortic valve replacement (AVR).²⁷ These data emphasize once more the importance of timely intervention.

Development of myocardial fibrosis with eventual negative impact on long-term outcome of AS has been a concern for a long time. However, how to include this into management strategies remains uncertain. Treibel *et al.* studied 133 patients with severe symptomatic AS undergoing SAVR. Cardiac magnetic resonance (CMR) with late gadolinium enhancement (LGE) and extracellular volume fraction (ECV) quantification were performed as well as histological examinations. Late gadolinium enhancement correlated with collagen volume fraction but not ECV. Both, LGE and ECV correlated independently with biomarkers. Extracellular volume fraction was also associated with worse LV remodelling, LVEF, and functional capacity. Combining both improved the identification of patients at risk.²⁸ In 116 patients with CMR repeated 1 year after AVR, focal fibrosis did not resolve while diffuse fibrosis and myocardial cellular hypertrophy regressed.²⁹ In a study of 674 patients with severe symptomatic AS undergoing SAVR or TAVI, LGE on CMR was independently associated with late mortality (two-fold higher).³⁰ Although these studies provide important new insight, whether we should screen asymptomatic patients with severe AS for early signs of fibrosis to optimize the timing of surgery can still not be answered from currently available data.

Patients with paradoxical low flow low gradient AS remain a challenging subgroup diagnostically as well as therapeutically. Many of these patients do not only have AS but other causes of LV myocardial damage, particularly arterial hypertension. Recent data suggest that cardiac amyloidosis is another associated disease one should think of. Castano *et al.* performed technetium-99m pyrophosphate cardiac scintigraphy prospectively on patients who underwent TAVI to screen for transthyretin cardiac amyloidosis (ATTR-A). Among 151 unselected patients 16% screened positive. These patients had thicker ventricles and lower stroke volume, more severe diastolic dysfunction, and lower ejection fraction.³¹ These findings gain even more importance in the view of a recent randomized controlled trial demonstrating that in patients with ATTR-A, tafamidis was associated with reductions in all-cause mortality and cardiovascular-related hospitalizations and reduced the decline in functional capacity and quality of life as compared with placebo.³²

Aortic regurgitation


The prevalence of aortic regurgitation (AR) is approximately 2% in patients over 70 years and increases with age. According to current guidelines, aortic valve surgery is indicated in severe AR if patients are

symptomatic, or asymptomatic patients present with reduced LVEF and/or marked dilatation of the LV or with aortic aneurysm.¹⁶ In patients with high/prohibitive surgical risk transcatheter intervention remains an option, however, due to the lack of calcifications and to dilatation of the annulus the procedural challenges make acute TAVI results less predictable and associated with higher rates of PVL and prosthesis embolization. Recent data suggest that TAVI using new-generation devices (both balloon- and self-expandable) is feasible in selected high surgical risk patients with pure AR. A multicentre registry including 331 patients showed improved device success rate, less post-procedural AR with new generation valves. Post-procedural AR was a strong predictor of mortality.³³

Mitral regurgitation

The burden of MR is increasing with age. The data on the frequency of MR vs. AS is varying between registries. In a population-based study from the US prevalence of MR was higher than of AS,³⁴ but the European registries EORP VHD I (2003) and VHD II (2018) demonstrated that MR was the second most frequent VHD after the AS (lung *et al.* Late-breaking science session at ESC Congress 2018). In a community cohort study, isolated MR was common and associated with excess mortality and frequent HF post-diagnosis in all patient subsets, even in those with normal LVEF and low comorbidity. Despite these poor outcomes, only a small minority of affected patients underwent mitral surgery (29% for primary and 5% for secondary MR) even in a community with all means of diagnosis and treatment readily available and accessible.³⁵ This suggests that in a wider population there might be a substantial unmet need for treatment for this disorder. Educational needs and application of guidelines in the management of patients with MR were addressed in a European mixed-methods study. Based on an online survey including 115 primary care physicians and 439 cardiologists and cardiac surgeons from seven European countries, systematic auscultation was dramatically underused for the early detection of MR. Surgical therapy was underused and medical therapy overused in primary MR, while optimization of medical therapy was frequently not advised in secondary MR. Indications for interventions were appropriate in most patients with primary MR but were unexpectedly frequent for secondary MR. These gaps identify important targets for future educational programmes.³⁶

Secondary (functional) MR was reported to be associated with adverse prognosis (47% mortality over 5 years) in patients with HF and to be a predictor of long-term mortality after adjustment for clinical [hazard ratio (HR) 1.61, 95% confidence interval (CI) 1.22–2.12; $P=0.001$], echocardiographic variables (HR 1.38, 95% CI 1.03–1.84; $P=0.03$), optimal medical therapy (OMT) and neurohumoral activation. This was most evident in patients with New York Heart Association (NYHA) II and III, moderately reduced LVEF, and elevated NT-pro BNP. These findings suggest that repair of MR might be more effective in patients in whom the valve incompetence has the highest impact on the prognosis and is the main factor associated with the progression of the disease.³⁷ On the other hand, there is a paucity of data on the long-term effect of surgical mitral valve repair on the clinical outcomes of secondary MR. The widespread use of transcatheter edge-to-edge repair



using the MitraClip (Abbott) system in patients with secondary MR was based on registry data showing favourable safety and clinical outcomes regarding MR reduction, and suggesting symptomatic improvement and ventricular remodelling. The efficacy was, however, lower for secondary than for primary MR and the predictors of adverse outcomes were device failure, low LVEF, and tricuspid regurgitation.^{38,39} There has been agreed that the definite role of transcatheter repair of secondary MR in clinical practice can only be elucidated in randomized clinical trials, and two of these were now recently published presenting **divergent results**.

MITRA.FR enrolled 304 patients with HF, severe secondary MR, and reduced LVEF (15–40%) who were on OMT and cardiac resynchronization therapy (CRT) as indicated.⁴⁰ They were randomly assigned 1:1 to additional MitraClip therapy or continued OMT alone. The procedure was performed with a low complication rate and high effectiveness. At discharge, 91.9% had MR $\leq 2+$. Nevertheless, there was no difference for the primary endpoint—death or unplanned re-hospitalization for HF at 12 months (54.6% vs. 51.3% for interventional and conservative treatment, respectively; death, 24.3% vs. 22.4%; re-hospitalization, 48.7% vs. 47.4%). NYHA class improved in both groups and was similar at 12 months. The study has the strength of a randomized trial with 99% follow-up regarding the primary endpoint and that it is an industry independent academic trial. The weakness is that a significant amount of follow-up data on echocardiographic outcome and functional status at 12 months were missing. The subgroup analyses in this trial showed consistently no effect of this therapy across pre-specified subgroups.

The Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (COAPT) study enrolled 614 patients with ischaemic (60, 7%) and non-ischaemic (39, 3%) HF and moderate-severe or severe secondary MR and were symptomatic (NYHA Class II–IV) despite maximally tolerated doses of OMT and CRT (36, 5%) as indicated by guidelines.⁴¹ Patients were randomly assigned to

the MitraClip procedure ($n=302$) or OMT alone ($n=312$). It showed a significant reduction of the primary endpoint of rehospitalization due to HF at 2 years (35.8% vs. 67.9%, HR 0.53; 95% CI 0.40–0.70, $P < 0.001$) with the number needed to treat to prevent one hospitalization of 3.1. There was also a significant reduction of all-cause mortality at 2 years, (29.1% vs. 46.1%, HR 0.62; 95% CI 0.46–0.82, $P < 0.001$) and improvement of the quality of life, functional capacity, improvement of MR, and reduction of LVEDV (prespecified secondary endpoints).

There were differences between the MITRA.FR and COAPT with regard to the sample size (304 vs. 614 patients) and duration of follow-up for primary Endpoint evaluation (12 months vs. 24 months). The primary endpoint in COAPT was all hospitalizations for HF (including recurrent events) and in MITRA.FR composite of death from any cause or unplanned hospitalization for HF. Regarding inclusion criteria, the definition of MR differed (effective regurgitant orifice area ≥ 20 mm² and/or regurgitant volume >30 mL vs. ≥ 30 mm² and >45 mL), as well as of LVEF (15–40% vs. 20–50%) and LV size. This resulted in on average larger ventricles (mean end-diastolic volume 135 mL/m² vs. 101 mL/m²) and less severe MR (effective regurgitant orifice area 31 ± 10 vs. 41 ± 15 mm²) while LVEF was similar ($33 \pm 7\%$ vs. $31 \pm 7\%$). Although the technical success rate in MITRA.FR was good compared with previous observational studies, it tended to be even higher in the COAPT study. Also, the enrolment strategy was different with central eligibility committee evaluating current treatment in every patient in the COAPT and more inclusive, real-life approach in MITRA.FR trial which could result in the observed improvement in the control arm in the latter study. Although these differences may have influenced outcomes, it remains unclear how the results of the two trials could differ so fundamentally (*Take home figure*). More studies will be required to resolve this controversy and identify the patient characteristics that make a benefit from valve repair in secondary MR likely. The ongoing RESHAPE-HF2 (NCT02444338) and Matterhorn (NCT02371512)

trials will likely help clarify the role of this technology in secondary MR.

In contrast to edge-to-edge repair, direct annuloplasty systems aim to achieve surgical-like results in the secondary MR by reducing the dilatation of the mitral annulus and correct the malcoaptation of the leaflets using undersized adjustable rings implanted by the transseptal catheter-based approach. A recent study by Messika-Zeitoun *et al.* investigated the safety and efficacy of the Cardioband™ Mitral Valve Reconstruction System (Edwards Lifesciences) in patients with HF (majority NYHA III-IV) and secondary MR. The technical success rate was 97% and in 52/60 patients a significant reduction of annulus diameter and MR severity (66% mild or less in-hospital and 61% at 1 year). The recurrence rate was 22% in 1 year. Importantly periprocedural complications (tamponade, VF, stroke, and MI) and anchor detachments were noted in the first cohort treated patients. This technology alone or in combination with edge-to-edge repair seems effective however the long-term clinical outcomes require further studies.⁴²

Persistent reduction of MR probably requires not only the intervention targeting the leaflets or annulus alone but either combination of both approaches or ultimately implantation of the TMVR. The early experience was hampered with valve thrombosis and regurgitation, but the improvement of the design and preprocedural planning allowed better outcomes. As reported by Bapat *et al.* Transcatheter mitral valve replacement with self-expandable transapical valve [Intrepid, Medtronic] with bovine pericardial leaflets in 50 patients with high or extreme operative risk proved feasible and effective in providing symptomatic relief. It was also safe with no periprocedural strokes or reinterventions.⁴³ The ongoing APOLLO trial which is planned to include transseptal TMVR will provide important data for this technology. A transseptal approach mitigating the use of high-profile transapical catheters is likely to improve the safety.

In severe primary MR, management of asymptomatic patients with preserved LV and no atrial fibrillation or pulmonary hypertension remains a matter of debate. Zilberszac *et al.* prospectively followed 280 such patients with a watchful waiting strategy for a median of 8 years. Compared with the age- and a gender-matched general population expected cumulative survival and early survival rates were even better in the study population. One-third was still event-free after 10 years.⁴⁴ These data support watchful waiting. However, it has to be emphasized that these patients had regular follow-up visits every 6 months in an expert centre and the results may only be expected in such a setting.

Mitral stenosis

The concept of implantation of **balloon-expandable valves** (Sapien, Edwards) in **high/prohibitive risk** patients with **severe mitral annular calcification (MAC)** was based on case series and registries. Guerrero *et al.* reported 1-year follow-up of 105 patients enrolled in multicentre **TMVR** in MAC Global Registry. Although the technical success rate was high and lead to significant symptomatic improvement, there was **substantial mortality** related to haemodynamically significant **LVOT obstruction in 11.2%** of patients such an approach need to be **further evaluated** and rigorous preprocedural planning is crucial.⁴⁵

Tricuspid regurgitation

Tricuspid regurgitation is a **significant clinical problem** affecting in Europe approximately 300 000 patients yearly.⁴⁶ There is a **growing recognition of this disease** and novel therapeutic options. **Fast progression** of tricuspid regurgitation (TR) has an adverse impact on survival, and **key risk factors** for fast TR progression have been identified (Figure 4).⁴⁷ It is accepted that **TV (TR) repair during left-sided valve intervention** is **beneficial** in terms of reduced mortality, however, increasing number of patients with MR deemed inoperable have also TR. In such cases, transcatheter repair on MV does not address the TV pathology and is ineffective in abating the symptoms of right HF. The concept of **simultaneous or staged transcatheter TV repair** using the MitraClip has been proven feasible and safe, however technically challenging. This approach requires careful preprocedural planning with angio-CT and **expert TOE guidance** during the procedure.⁴⁸ Other transcatheter devices, such as PASCAL (edge-to-edge repair system), Cardioband (direct annuloplasty), or caval approach (one or two TAVI devices implanted within the stents in caval veins) have been recently tested with promising early results (reduction of TR severity, improved symptoms) in selected high risk patients.^{49–51} The majority of patients are treated on a compassionate basis and have multiple comorbidities, and the impact of TR repair requires further evaluation. The TriValve (Transcatheter Tricuspid Valve Therapies) registry evaluated 106 high-risk patients treated with multiple transcatheter devices and showed safety, moderate (62%) procedural success and reduction of HF symptoms.⁵²

Not only secondary TR coexisting with the disease of other valves remains a significant clinical problem, but also **isolated TV disease** which confers an increased risk of mortality and **shows increasing prevalence**. Isolated TV surgery is associated with a high perioperative risk (in-hospital mortality of 8.8%) and does not diminish over time despite the growing number of surgical procedures.⁵³ Similarly to MV interventions, the key step is patient selection. At the current stage, the most appropriate would be high surgical risk patients without right ventricular failure and pulmonary hypertension. Finally, it has to be emphasized that for secondary TR similar to secondary MR, only its association with worse outcome has been demonstrated while it remains uncertain whether its reduction by intervention can improve outcome.

Non-valve specific issues

Paravalvular regurgitation (PVL) is an uncommon complication of **surgical valve** replacement requiring repair in **2–5%** of cases. Repeated surgery is associated with significant risk. **Transcatheter closure** is a valid treatment option after exclusion of active endocarditis in patients with acceptable anatomy. However, data on the periprocedural and long-term outcomes were based on the registries using heterogenous definitions.¹⁶ Recently, the PVL Academic Research Consortium set standards for the assessment of disease severity, data collection, and updated endpoint definitions.⁵⁴

Diagnosis of prosthetic valve endocarditis (PVE) remains **challenging**. A multicentre study including 160 patients with suspicion of PVE confirmed the diagnostic value of visual and quantitative assessment of FDG PET/CT in this setting and highlights the importance of early




Figure 4 Independent predictors of the fast vs. slow development of tricuspid regurgitation (A) and event-free survival according to the rate of progression of tricuspid regurgitation (Group 1: ≤ 1.2 years; Group 2: 1.3–4.7 years; Group 3: 4.8–8.9 years; Group 4: ≥ 9.0 years) (B). Reprinted with permission from Pihadi et al.⁴⁷

implementation in the diagnostic work-up to prevent confounding effects of low inflammatory activity due to prolonged antibiotic therapy. Recent valve implantation was not a significant predictor of false positive interpretations, but surgical adhesives used during implantation were.^{55,56}

The incidence of infectious endocarditis (IE) in the UK is estimated to be 36.2/million/year. The risk factors of mortality in IE patients are the previous history of IE, prosthetic valve, and history of valve repair.⁵⁷ Recent data from the Danish nationwide registries allowed improved identification of IE risk factors in moderate and high-risk populations in comparison to the general population. There was a stepwise increase of IE risk in these populations. The risk factors for IE in moderate risk group were VHD, an implantable device, hypertrophic cardiomyopathy and the risk of IE was higher than the general population but lower than in high-risk group.^{58,59}

In a randomized, noninferiority, multicentre trial, 400 adults in stable condition who had endocarditis on the left side of the heart caused by *Streptococcus*, *Enterococcus faecalis*, *Staphylococcus aureus*, or coagulase-negative *Staphylococci* treated for at least 10 days with intravenous antibiotics were assigned to either continued intravenous or to switch to oral treatment. The primary composite outcome of all-cause mortality, unplanned surgery, embolic events, or relapse of bacteraemia occurred in 12.1% vs. 9.0% confirming noninferiority of switching to oral treatment. These findings could have major impact on clinical practice.⁶⁰

Pulmonary hypertension (PH) may persist after correction of VHD. It is then associated with increased morbidity and mortality. Whether targeted PH treatment is effective in this setting remains uncertain. In a multicentric, randomized, placebo-controlled trial including 200 patients with successful valve replacement or repair procedure at least 1 year before inclusion, a mean pulmonary artery pressure still ≥ 30 mmHg

(57% with a resistance >3 Wood Units, i.e. combined post and pre-capillary PH) were assigned to sildenafil 40 mg three times daily or placebo for 6 months. The primary endpoint was a composite clinical score combining death, hospital admission for HF, change in functional class, and patient global self-assessment. Patients on sildenafil had a significantly worse outcome indicating that this treatment cannot be recommended for this patient group.⁶¹

Perspectives

There is a growing awareness of the burden of VHD worldwide, and the adoption of minimally invasive treatment options will be expanding thanks to new device technologies and progress of imaging. Mitral and TV interventions are gaining momentum in high risk and inoperable patients but will need to overcome more technical challenges than aortic valve interventions due to the more complex and variable anatomy.

Conflict of interest: W.W. reports personal fees from Medtronic, personal fees from Abbott, personal fees from Edwards Lifesciences, outside the submitted work. H.B. reports personal fees from Edwards Life Sciences, personal fees from Abbott, personal fees from Medtronic, personal fees from Action, outside the submitted work.

References

- Gaede L, Blumenstein J, Liebetrau C, Dorr O, Kim WK, Nef H, Husser O, Elsasser A, Hamm CW, Mollmann H. Outcome after transcatheter aortic valve implantation in 2016. *Eur Heart J* 2018;**39**:667–675.
- Tarantini G, Nai Fovino L, Gersh BJ. Transcatheter aortic valve implantation in lower-risk patients: what is the perspective? *Eur Heart J* 2018;**39**:658–666.
- Waksman R, Rogers T, Torguson R, Gordon P, Ehsan A, Wilson SR, Goncalves J, Levitt R, Hahn C, Parikh P, Billfinger T, Butzel D, Buchanan S, Hanna N, Garrett R, Asch F, Weissman G, Ben-Dor I, Shults C, Bastian R, Craig PE, Garcia-Garcia HM, Kolm P, Zou Q, Satler LF, Corso PJ. Transcatheter aortic valve replacement in low-risk patients with symptomatic severe aortic stenosis. *J Am Coll Cardiol* 2018;**72**:2095–2105.

4. Serruys PW, Modolo R, Reardon M, Miyazaki Y, Windecker S, Popma J, Chang Y, Kleiman NS, Lilly S, Amrane H, Boonstra PW, Kappetein AP, Onuma Y, Sondergaard L, van Mieghem N. One-year outcomes of patients with severe aortic stenosis and an STS-PROM of less than three percent in the SURTAVI trial. *EuroIntervention* 2018;**14**:877–883.
5. Eltchaninoff H, Durand E, Avinee G, Tron C, Litzler PY, Bauer F, Dacher JN, Werhlin C, Bouhazam N, Bettinger N, Candolfi P, Cribier A. Assessment of structural valve deterioration of transcatheter aortic bioprosthetic balloon-expandable valves using the new European consensus definition. *EuroIntervention* 2018;**14**:e264–e271.
6. Holy EW, Kebernik J, Abdelghani M, Stampfli SF, Hellermann J, Allali A, El-Mawardi M, Sachse S, Luscher TF, Tanner FC, Richardt G, Abdel-Wahab M. Long-term durability and haemodynamic performance of a self-expanding transcatheter heart valve beyond five years after implantation: a prospective observational study applying the standardised definitions of structural deterioration and valve failure. *EuroIntervention* 2018;**14**:e390–e396.
7. van Rosendaal PJ, Delgado V, Bax JJ. Pacemaker implantation rate after transcatheter aortic valve implantation with early and new-generation devices: a systematic review. *Eur Heart J* 2018;**39**:2003–2013.
8. Eggebrecht H, Vaquerizo B, Moris C, Bossone E, Lämmer J, Czerny M, Zierer A, Schrófel H, Kim WK, Walther T, Scholtz S, Rudolph T, Hengstenberg C, Kempfert J, Spaziano M, Lefevre T, Bleiziffer S, Schofer J, Mehilli J, Seiffert M, Naber C, Biancari F, Eckner D, Cornet C, Lhermusier T, Philippart R, Siljander A, Giuseppe Cerillo A, Blackman D, Chieffo A, Kahlert P, Czerwinska-Jelonkiewicz K, Szymanski P, Landes U, Kornowski R, D'Onofrio A, Kaulfersch C, Søndergaard L, Mylotte D, Mehta RH, De Backer O; European Registry on Emergent Cardiac Surgery during TAVI (EuRECS-TAVI). Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on Emergent Cardiac Surgery during TAVI (EuRECS-TAVI). *Eur Heart J* 2018;**39**:676–684.
9. Arsalan M, Kim WK, Van Linden A, Liebetau C, Pollock BD, Filardo G, Renker M, Mollmann H, Doss M, Fischer-Rasokat U, Skwara A, Hamm CW, Walther T. Predictors and outcome of conversion to cardiac surgery during transcatheter aortic valve implantation. *Eur J Cardiothorac Surg* 2018;**54**:267–272.
10. Bestehorn K, Eggebrecht H, Fleck E, Bestehorn M, Mehta RH, Kuck KH. Volume-outcome relationship with transfemoral transcatheter aortic valve implantation (TAVI): insights from the compulsory German Quality Assurance Registry on Aortic Valve Replacement (AQUA). *EuroIntervention* 2017;**13**:914–920.
11. Durko AP, Osnabrügge RL, Van Mieghem NM, Milojevic M, Mylotte D, Nkomo VT, Pieter Kappetein A. Annual number of candidates for transcatheter aortic valve implantation per country: current estimates and future projections. *Eur Heart J* 2018;**39**:2635–2642.
12. D'Ascenzo F, Verardi R, Visconti M, Conrotto F, Scacciarella P, Dziewierz A, Stefanini GG, Paradis JM, Omede P, Kodali S, D'Amico M, Rinaldi M, Salizzoni S. Independent impact of extent of coronary artery disease and percutaneous revascularisation on 30-day and one-year mortality after TAVI: a meta-analysis of adjusted observational results. *EuroIntervention* 2018;**14**:e1169–e1177.
13. Yamanaka F, Shishido K, Ochiai T, Moriyama N, Yamazaki K, Sugitani A, Tani T, Tobita K, Mizuno S, Tanaka Y, Murakami M, Takahashi S, Yamazaki S, Saito S. Instantaneous wave-free ratio for the assessment of intermediate coronary artery stenosis in patients with severe aortic valve stenosis: comparison with myocardial perfusion scintigraphy. *JACC Cardiovasc Interv* 2018;**11**:2032–2040.
14. Witberg G, Zusman O, Codner P, Assali A, Kornowski R. Impact of coronary artery revascularization completeness on outcomes of patients with coronary artery disease undergoing transcatheter aortic valve replacement: a meta-analysis of studies using the residual SYNTAX score (Synergy Between PCI With Taxus and Cardiac Surgery). *Circ Cardiovasc Interv* 2018;**11**:e006000.
15. Bauer T, Linke A, Sievert H, Kahlert P, Hambrecht R, Nickenig G, Hauptmann KE, Sack S, Gerckens U, Schneider S, Zeymer U, Zahn R. Comparison of the effectiveness of transcatheter aortic valve implantation in patients with stenotic bicuspid versus tricuspid aortic valves (from the German TAVI Registry). *Am J Cardiol* 2014;**113**:518–521.
16. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Jung B, Lancellotti P, Lansac E, Rodriguez Munoz D, Rosenhek R, Sjogren J, Tornos Mas P, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL; ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J* 2017;**38**:2739–2791.
17. Tuzcu EM, Kapadia SR, Vemulapalli S, Carroll JD, Holmes DR Jr, Mack MJ, Thourani VH, Grover FL, Brennan JM, Suri RM, Dai D, Svensson LG. Transcatheter aortic valve replacement of failed surgically implanted bioprostheses: the STS/ACC registry. *J Am Coll Cardiol* 2018;**72**:370–382.
18. Ribeiro HB, Rodes-Cabau J, Blanke P, Leipsic J, Kwan Park J, Bapat V, Makkar R, Simonato M, Barbanti M, Schofer J, Bleiziffer S, Latib A, Hildick-Smith D, Presbitero P, Windecker S, Napodano M, Cerillo AG, Abdel-Wahab M, Tchetché D, Fiorina C, Sinning JM, Cohen MG, Guerrero ME, Whisenant B, Nietlispach F, Palma JH, Nombela-Franco L, de Weger A, Kass M, Sandoli de Brito F Jr, Lemos PA, Kornowski R, Webb J, Dvir D. Incidence, predictors, and clinical outcomes of coronary obstruction following transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: insights from the VIVID registry. *Eur Heart J* 2018;**39**:687–695.
19. Jabbar R, Tanaka A, Finkelstein A, Mack M, Tamburino C, Van Mieghem N, de Backer O, Testa L, Gatto P, Purita P, Rahhab Z, Veulemans V, Stundl A, Barbanti M, Nerla R, Sinning JM, Dvir D, Tarantini G, Szerlip M, Scholtz W, Scholtz S, Tchetché D, Castriota F, Butter C, Søndergaard L, Abdel-Wahab M, Sievert H, Alfieri O, Webb J, Rodés-Cabau J, Colombo A, Latib A. Delayed coronary obstruction after transcatheter aortic valve replacement. *J Am Coll Cardiol* 2018;**71**:1513–1524.
20. Geis NA, Kiriakou C, Chorianopoulos E, Pleger ST, Katus HA, Bekerredjian R. Feasibility and safety of vitamin K antagonist monotherapy in atrial fibrillation patients undergoing transcatheter aortic valve implantation. *EuroIntervention* 2017;**12**:2058–2066.
21. D'Ascenzo F, Benedetto U, Bianco M, Conrotto F, Moretti C, D'Onofrio A, Agrifoglio M, Colombo A, Ribichini F, Tarantini G, D'Amico M, Salizzoni S, Rinaldi M. Which is the best antiaggregant or anticoagulant therapy after TAVI? A propensity-matched analysis from the ITER registry. The management of DAPT after TAVI. *EuroIntervention* 2017;**13**:e1392–e1400.
22. Overtchouk P, Guedeny P, Rouanet S, Verhoye JP, Lefevre T, Van Belle E, Eltchaninoff H, Gilard M, Leprince P, Jung B, Barthelemy O, Le Breton H, Souteyrand G, Vicaut E, Montalescot G, Collet JP. Long-term mortality and early valve dysfunction according to anticoagulation use: the FRANCE-TAVI registry. *J Am Coll Cardiol* 2018.
23. Ahmed A, Sorajja P, Garberich RF, Farivar RS, Harris KM, Gossel M. Association of guideline adherence for serial evaluations with survival and adverse clinical events in patients with asymptomatic severe aortic stenosis. *JAMA Cardiol* 2017;**2**:1141–1146.
24. Lancellotti P, Magne J, Dulgheru R, Clavel MA, Donal E, Vannan MA, Chambers J, Rosenhek R, Habib G, Lloyd G, Nistri S, Garbi M, Marchetta S, Fattouch K, Coisne A, Montaigne D, Modine T, Davin L, Gach O, Radermecker M, Liu S, Gillam L, Rossi A, Galli E, Ilardi F, Tastet L, Capoulade R, Zilberszac R, Vollema EM, Delgado V, Cosyns B, Lafitte S, Bernard A, Pierard LA, Bax JJ, Pibarot P, Oury C. Outcomes of patients with asymptomatic aortic stenosis followed up in heart valve clinics. *JAMA Cardiol* 2018.
25. Levy F, Bohbot Y, Sanhadji K, Rusinaru D, Ringle A, Delpierre Q, Smaali S, Gun M, Marechaux S, Tribouilloy C. Impact of pulmonary hypertension on long-term outcome in patients with severe aortic stenosis. *Eur Heart J Cardiovasc Imaging* 2018;**19**:553–561.
26. Goulbraire C, Melissopoulou M, Lobo D, Kubota N, Verdonk C, Cimadevilla C, Codogno I, Brochet E, Vahanian A, Messika-Zeitoun D. Prognostic value of exercise-stress echocardiography in asymptomatic patients with aortic valve stenosis. *JACC Cardiovasc Imaging* 2018;**11**:787–795.
27. Genereux P, Pibarot P, Redfors B, Mack MJ, Makkar RR, Jaber WA, Svensson LG, Kapadia S, Tuzcu EM, Thourani VH, Babaliaros V, Herrmann HC, Szeto VY, Cohen DJ, Lindman BR, McAndrew T, Alu MC, Douglas PS, Hahn RT, Kodali SK, Smith CR, Miller DC, Webb JG, Leon MB. Staging classification of aortic stenosis based on the extent of cardiac damage. *Eur Heart J* 2017;**38**:3351–3358.
28. Treibel TA, Lopez B, Gonzalez A, Menacho K, Schofield RS, Ravassa S, Fontana M, White SK, DiSalvo C, Roberts N, Ashworth MT, Diez J, Moon JC. Reappraising myocardial fibrosis in severe aortic stenosis: an invasive and non-invasive study in 133 patients. *Eur Heart J* 2018;**39**:699–709.
29. Treibel TA, Kozor R, Schofield R, Benedetti G, Fontana M, Bhuvana AN, Sheikh A, Lopez B, Gonzalez A, Manisty C, Lloyd G, Kellman P, Diez J, Moon JC. Reverse myocardial remodeling following valve replacement in patients with aortic stenosis. *J Am Coll Cardiol* 2018;**71**:860–871.
30. Musa TA, Treibel TA, Vassiliou VS, Captur G, Singh A, Chin C, Dobson LE, Pica S, Loudon M, Malley T, Rigolli M, Foley JRJ, Bijsterveld P, Law GR, Dweck MR, Myerson SG, McCann GP, Prasad SK, Moon JC, Greenwood JP. Myocardial scar and mortality in severe aortic stenosis: data from the BSCMR valve consortium. *Circulation* 2018.
31. Castano A, Narotsky DL, Hamid N, Khaliq OK, Morgenstern R, DeLuca A, Rubin J, Chiuazan C, Nazif T, Vahl T, George I, Kodali S, Leon MB, Hahn R, Bokhari S, Maurer MS. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. *Eur Heart J* 2017;**38**:2879–2887.
32. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Wittesler R, Damsy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C; ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. *N Engl J Med* 2018;**379**:1007–1016.

33. Yoon SH, Schmidt T, Bleiziffer S, Schofer N, Fiorina C, Munoz-Garcia AJ, Yzeiraj E, Amat-Santos IJ, Tchetché D, Jung C, Fujita B, Mangieri A, Deutsch MA, Ubben T, Deuschl F, Kuwata S, De Biase C, Williams T, Dhoble A, Kim WK, Ferrari E, Barbanti M, Vollema EM, Miceli A, Giannini C, Attizzani GF, Kong WK, Gutierrez-Ibanez E, Jimenez Diaz VA, Wijeyundera HC, Kaneko H, Chakravarty T, Makar M, Sievert H, Hengstenberg C, Prendergast BD, Vincent F, Abdel-Wahab M, Nombela-Franco L, Silaschi M, Tarantini G, Butter C, Ensminger SM, Hildick-Smith D, Petronio AS, Yin WH, De Marco F, Testa L, Van Mieghem NM, Whisenant BK, Kuck KH, Colombo A, Kar S, Moris C, Delgado V, Maisano F, Nietlispach F, Mack MJ, Schofer J, Schaefer U, Bax JJ, Frerker C, Latib A, Makkar RR. Transcatheter aortic valve replacement in pure native aortic valve regurgitation. *J Am Coll Cardiol* 2017;**70**:2752–2763.
34. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. *Lancet* 2006;**368**:1005–1011.
35. Dziadzko V, Clavel MA, Dziadzko M, Medina-Inojosa JR, Michelena H, Maalouf J, Nkomo V, Thapa P, Enriquez-Sarano M. Outcome and undertreatment of mitral regurgitation: a community cohort study. *Lancet* 2018;**391**:960–969.
36. lung B, Delgado V, Lazure P, Murray S, Sirnes PA, Rosenhek R, Price S, Metra M, Carrera C, De Bonis M, Haude M, Hindricks G, Bax J, Vahanian A. Educational needs and application of guidelines in the management of patients with mitral regurgitation. A European mixed-methods study. *Eur Heart J* 2018;**39**:1295–1303.
37. Goliash G, Bartko PE, Pavo N, Neuhold S, Wurm R, Mascherbauer J, Lang IM, Strunk G, Hulsman M. Refining the prognostic impact of functional mitral regurgitation in chronic heart failure. *Eur Heart J* 2018;**39**:39–46.
38. Sorajja P, Vemulapalli S, Feldman T, Mack M, Holmes DR Jr, Stebbins A, Kar S, Thourani V, Ailawadi G. Outcomes with transcatheter mitral valve repair in the United States: an STS/ACC TVT registry report. *J Am Coll Cardiol* 2017;**70**:2315–2327.
39. Puls M, Lubos E, Boekstegers P, von Bardeleben RS, Ouarrak T, Butter C, Zuern CS, Bekerredjian R, Sievert H, Nickenig G, Eggebrecht H, Senges J, Schillinger W. One-year outcomes and predictors of mortality after MitraClip therapy in contemporary clinical practice: results from the German transcatheter mitral valve interventions registry. *Eur Heart J* 2016;**37**:703–712.
40. Obadia JF, Messika-Zeitoun D, Leurent G, lung B, Bonnet G, Piriou N, Lefevre T, Piot C, Rouleau F, Carrie D, Nejari M, Ohlmann P, Leclercq F, Saint Etienne C, Teiger E, Leroux L, Karam N, Michel N, Gilard M, Donal E, Trochu JN, Cormier B, Armoiry X, Boutitie F, Maucort-Boulch D, Barnel C, Samson G, Guerin P, Vahanian A, Mewton N, Investigators M-F. Percutaneous repair or medical treatment for secondary mitral regurgitation. *N Engl J Med* 2018.
41. Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, Whisenant B, Grayburn PA, Rinaldi M, Kapadia SR, Rajagopal V, Sarembock IJ, Brieke A, Marx SO, Cohen DJ, Weissman NJ, Mack MJ, Investigators C. Transcatheter mitral-valve repair in patients with heart failure. *N Engl J Med* 2018.
42. Messika-Zeitoun D, Nickenig G, Latib A, Kuck KH, Baldus S, Schueler R, La Canna G, Agricola E, Kreidel F, Huntgeburth M, Zuber M, Verta P, Grayburn P, Vahanian A, Maisano F. Transcatheter mitral valve repair for functional mitral regurgitation using the Cardioband system: 1 year outcomes. *Eur Heart J* 2018.
43. Bapat V, Rajagopal V, Meduri C, Farivar RS, Walton A, Duffy SJ, Gooley R, Almeida A, Reardon MJ, Kleiman NS, Spargias K, Pattakos S, Ng MK, Wilson M, Adams DH, Leon M, Mack MJ, Chenoweth S, Sorajja P; Intrepid Global Pilot Study Investigators. Early experience with new transcatheter mitral valve replacement. *J Am Coll Cardiol* 2018;**71**:12–21.
44. Zilberszac R, Heinze G, Binder T, Laufer G, Gabriel H, Rosenhek R. Long-term outcome of active surveillance in severe but asymptomatic primary mitral regurgitation. *JACC Cardiovasc Imaging* 2018;**11**:1213–1221.
45. de Jaegere P, Rajani R, Prendergast B, Van Mieghem NM. Patient-specific computer modeling for the planning of transcatheter mitral valve replacement. *J Am Coll Cardiol* 2018;**72**:956–958.
46. Rodes-Cabau J, Taramasso M, O'Gara PT. Diagnosis and treatment of tricuspid valve disease: current and future perspectives. *Lancet* 2016;**388**:2431–2442.
47. Prihadi EA, van der Bijl P, Guroy E, Abou R, Mara Vollema E, Hahn RT, Stone GW, Leon MB, Ajmone Marsan N, Delgado V, Bax JJ. Development of significant tricuspid regurgitation over time and prognostic implications: new insights into natural history. *Eur Heart J* 2018;**39**:3574–3581.
48. Nickenig G, Kowalski M, Hausleiter J, Braun D, Schofer J, Yzeiraj E, Rudolph V, Friedrichs K, Maisano F, Taramasso M, Fam N, Bianchi G, Bedogni F, Denti P, Alfieri O, Latib A, Colombo A, Hammerstingl C, Schueler R. Transcatheter treatment of severe tricuspid regurgitation with the edge-to-edge mitralclip technique. *Circulation* 2017;**135**:1802–1814.
49. Lauten A, Dreger H, Schofer J, Grube E, Beckhoff F, Jakob P, Sinning JM, Stangl K, Figulla HR, Laule M. Caval valve implantation for treatment of severe tricuspid regurgitation. *J Am Coll Cardiol* 2018;**71**:1183–1184.
50. Fam NP, Ho EC, Zahrani M, Samargandy S, Connelly KA. Transcatheter tricuspid valve repair with the PASCAL system. *JACC Cardiovasc Interv* 2018;**11**:407–408.
51. Schueler R, Hammerstingl C, Werner N, Nickenig G. Interventional direct annuloplasty for functional tricuspid regurgitation. *JACC Cardiovasc Interv* 2017;**10**:415–416.
52. Taramasso M, Hahn RT, Alessandrini H, Latib A, Attinger-Toller A, Braun D, Brochet E, Connelly KA, Denti P, Deuschl F, Englmaier A, Fam N, Frerker C, Hausleiter J, Juliard JM, Kaple R, Kreidel F, Kuck KH, Kuwata S, Ancona M, Malasa M, Nazif T, Nickenig G, Nietlispach F, Pozzoli A, Schaefer U, Schofer J, Schueler R, Tang G, Vahanian A, Webb JG, Yzeiraj E, Maisano F, Leon MB. The International Multicenter TriValve Registry: which patients are undergoing transcatheter tricuspid repair? *JACC Cardiovasc Interv* 2017;**10**:1982–1990.
53. Zack CJ, Fender EA, Chandrashekar P, Reddy YNV, Bennett CE, Stulak JM, Miller VM, Nishimura RA. National trends and outcomes in isolated tricuspid valve surgery. *J Am Coll Cardiol* 2017;**70**:2953–2960.
54. Ruiz CE, Hahn RT, Berrebi A, Borer JS, Cutlip DE, Fontana G, Gerosa G, Ibrahim R, Jelinin V, Jilaliawi H, Jolicœur EM, Kliger C, Kronzon I, Leipsic J, Maisano F, Millan X, Nataf P, O'Gara PT, Pibarot P, Ramee SR, Rihal CS, Rodes-Cabau J, Sorajja P, Suri R, Swain JA, Turi ZG, Tuzcu EM, Weissman NJ, Zamorano JL, Serruys PW, Leon MB; Paravalvular Leak Academic Research Consortium. Clinical trial principles and endpoint definitions for paravalvular leaks in surgical prosthesis. *Eur Heart J* 2018;**39**:1224–1245.
55. Swart LE, Gomes A, Scholtens AM, Sinha B, Tanis W, Lam M, van der Vlugt MJ, Streukens SAF, Aarntzen E, Bucerius J, van Assen S, Bleeker-Rovers CP, van Geel PP, Krestin GP, van Melle JP, Roos-Hesselink JW, Slart R, Glaudemans A, Budde RPJ. Improving the diagnostic performance of (18)F-FDG PET/CT in prosthetic heart valve endocarditis. *Circulation* 2018.
56. Swart LE, Scholtens AM, Tanis W, Nieman K, Bogers A, Verzijlbergen FJ, Krestin GP, Roos-Hesselink JW, Budde RPJ. ¹⁸F-fluorodeoxyglucose positron emission/computed tomography and computed tomography angiography in prosthetic heart valve endocarditis: from guidelines to clinical practice. *Eur Heart J* 2018;**39**:3739–3749.
57. Thornhill MH, Jones S, Prendergast B, Baddour LM, Chambers JB, Lockhart PB, Dayer MJ. Quantifying infective endocarditis risk in patients with predisposing cardiac conditions. *Eur Heart J* 2018;**39**:586–595.
58. Ostergaard L, Valeur N, Ihlemann N, Bundgaard H, Gislason G, Torp-Pedersen C, Bruun NE, Sondergaard L, Kober L, Fosbol EL. Incidence of infective endocarditis among patients considered at high risk. *Eur Heart J* 2018;**39**:623–629.
59. Ostergaard L, Valeur N, Wang A, Bundgaard H, Aslam M, Gislason G, Torp-Pedersen C, Bruun NE, Sondergaard L, Kober L, Fosbol EL. Incidence of infective endocarditis in patients considered at moderate risk. *Eur Heart J* 2018.
60. Iversen K, Ihlemann N, Gill SU, Madsen T, Elming H, Jensen KT, Bruun NE, Hofsten DE, Fursted K, Christensen JJ, Schultz M, Klein CF, Fosboll EL, Rosenvinge F, Schonheyder HC, Kober L, Torp-Pedersen C, Helweg-Larsen J, Tonder N, Moser C, Bundgaard H. Partial oral versus intravenous antibiotic treatment of endocarditis. *N Engl J Med* 2018.
61. Bermejo J, Yotti R, García-Orta R, Sánchez-Fernández PL, Castaño M, Segovia-Cubero J, Escribano-Subías P, San Román JA, Borrás X, Alonso-Gómez A, Botas J, Crespo-Leiro MG, Velasco S, Bayés-Genís A, López A, Muñoz-Aguilera R, de Teresa E, González-Juanatey JR, Evangelista A, Mombiela T, González-Mansilla A, Elízaga J, Martín-Moreiras J, González-Santos JM, Moreno-Escobar E, Fernández-Avilés F; Sildenafil for Improving Outcomes after VALvular Correction (SIOVAC) investigators. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. *Eur Heart J* 2018;**39**:1255–1264.